Informações:
Falhas:
ID
13158
Descrição
Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes; ODM derived from: https://clinicaltrials.gov/show/NCT00038870
Link
https://clinicaltrials.gov/show/NCT00038870
Palavras-chave
Versões (1)
- 20/01/2016 20/01/2016 -
Titular dos direitos
CC BY-NC 3.0
Transferido a
20 de janeiro de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Acute Myelogenous Leukemia NCT00038870
Eligibility Acute Myelogenous Leukemia NCT00038870
- StudyEvent: Eligibility
Similar models
Eligibility Acute Myelogenous Leukemia NCT00038870
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
AML patients either after first relapse or at diagnosis a) with high-risk cytogenetics such as -7, -5, +8, chromosome 9 or 11 abnormality, or b) wbc > 50,000, or c) age > 60 years*
Item
aml patients either after first relapse or at diagnosis a) with high-risk cytogenetics such as -7, -5, +8, chromosome 9 or 11 abnormality, or b) wbc > 50,000, or c) age > 60 years*.
boolean
C0023467 (UMLS CUI [1])
> 1000 circulating blasts/mm at diagnosis
Item
aml patients are eligible for cell collection if they have > 1000 circulating blasts/mm at diagnosis.
boolean
C0523113 (UMLS CUI [1])
CML in myeloid blast crisis
Item
cml patients in myeloid blast crisis with > 1000 circulating blasts/mm.
boolean
C0023474 (UMLS CUI [1])
creatinine, bilirubin
Item
creatinine <2, bilirubin <3.
boolean
C0201976 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C1278039 (UMLS CUI [2])
age
Item
age >18.
boolean
C0001779 (UMLS CUI [1])
factors which would prevent the patient from receiving or cooperating with the full course of therapy or understanding the informed consent procedure
Item
factors which would prevent the patient from receiving or cooperating with the full course of therapy or understanding the informed consent procedure.
text
C0021430 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
need for corticosteroids
Item
concurrent or expected need for therapy with corticosteroids.
text
C0001617 (UMLS CUI [1])
HIV
Item
positive antibody to human immunodeficiency virus i.
text
C0019682 (UMLS CUI [1])
APL
Item
acute promyelocytic leukemia (fab-m3).
text
C0023487 (UMLS CUI [1])
comorbidity
Item
history of overt cardiac failure, systemic autoimmune disease or expected need for steroid therapy.
text
C0009488 (UMLS CUI [1])
inversion 16 or t(8;21)
Item
patients >60 will be eligible for study but if found to have good prognosis cytogenetics (inversion (16) or t(8;21)) will subsequently be withdrawn from study and treated off protocol without infusion of autologous leukemia derived cells.
text
C4014436 (UMLS CUI [1])
C3897139 (UMLS CUI [2])
C3897139 (UMLS CUI [2])